Methylprednisolone

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.4. Hormones and antihormones

EMLc ATC codes: H02AB04

Indication	Burkitt lymphoma including Burkitt leukaemia ICD11 code: 2A85.6
INN	Methylprednisolone
Medicine type	Chemical agent
List type	Complementary
Formulations	**Parenteral > General injections > IV:** 40 mg in vial (as sodium succinate) (EMLc) ; 125 mg in vial (as sodium succinate) (EMLc)
EML status history	First added in 2021 (TRS 1035) Changed in 2025 (TRS 1064)
Sex	All
Age	Children (1 month - 12 years)
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Tags	Cancer
Wikipedia	Methylprednisolone
DrugBank	Methylprednisolone

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of methylprednisolone 125 mg powder for injection to the EMLc; - the deletion of methylprednisolone injection 80 mg/mL from the EMLc; - update the description of methylprednisolone 40 mg injection (powder for injection in vial).